Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest
06:39pm, Tuesday, 30'th Jul 2024
The benefit of Eisai and Biogen's Alzheimer's drug Leqembi in patients with early-stage Alzheimer's appears to increase with continued use with no new safety issues, according to three-year data prese
51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
02:35pm, Tuesday, 30'th Jul 2024
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
Countdown to Biogen (BIIB) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
10:21am, Tuesday, 30'th Jul 2024
Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer's Disease
07:30am, Tuesday, 30'th Jul 2024
CAMBRIDGE, Mass. and BREA, Calif. and TOKYO, July 30, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB), Beckman Coulter, Inc. and Fujirebio announced a collaboration to potentially identify and dev
3 Biotech Names With Potential Catalysts By Year End
03:32pm, Monday, 29'th Jul 2024
The huge sector rotation we have seen in the market over the past few weeks has significantly benefited the SPDR® S&P Biotech ETF. If this trend continues, small-cap names within the sector should co
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
11:35am, Monday, 29'th Jul 2024
Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
05:30am, Monday, 29'th Jul 2024
Biogen is counting on its Alzheimer's drug, Leqembi, to jumpstart growth -- and sales are progressing in the United States. But European regulators consider the drug too risky.
European drug regulator rejects Alzheimer's treatment Leqembi from Biogen, Eisai
08:42am, Friday, 26'th Jul 2024
European drug regulators rejected the Alzheimer's treatment Leqembi from Biogen and Eisai, creating another hurdle for the companies as they scramble to boost uptake of the therapy in the U.S. The E
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
07:20am, Friday, 26'th Jul 2024
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Mas
EU medicines regulator rejects Eisai-Biogen Alzheimer's drug
06:49am, Friday, 26'th Jul 2024
The European Union's drugs regulator on Friday rejected Eisai and Biogen's breakthrough treatment for early Alzheimer's disease, in a blow to the drugmakers as take-up in the U.S. has been slower than
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Biogen Inc. (NASDAQ: BIIB) on be
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for
11:07am, Thursday, 25'th Jul 2024
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biogen and Sage to scrap neurological disorder drug development after trial failure
06:46am, Wednesday, 24'th Jul 2024
Biogen and Sage Therapeutics do not plan to conduct further studies for their neurological disorder drug after it failed in a mid-stage trial, the drugmakers said on Wednesday.
Levi & Korsinsky Notifies Biogen Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIIB
05:15pm, Monday, 22'nd Jul 2024
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow t
